AbbVie Inc. $ABBV Shares Sold by WoodTrust Financial Corp

WoodTrust Financial Corp cut its stake in AbbVie Inc. (NYSE:ABBV) by 74.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,929 shares of the company’s stock after selling 14,162 shares during the quarter. WoodTrust Financial Corp’s holdings in AbbVie were worth $1,141,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. increased its position in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC boosted its stake in AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after buying an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after acquiring an additional 1,517,222 shares during the last quarter. Norges Bank purchased a new stake in shares of AbbVie in the 2nd quarter valued at approximately $4,288,200,000. Finally, Raymond James Financial Inc. boosted its position in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research analyst reports. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Evercore ISI raised their target price on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Finally, DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research note on Tuesday, November 4th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $247.84.

AbbVie Price Performance

Shares of NYSE ABBV opened at $214.38 on Friday. The stock’s 50-day moving average is $226.80 and its two-hundred day moving average is $216.28. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a market cap of $378.89 billion, a price-to-earnings ratio of 162.41, a price-to-earnings-growth ratio of 0.89 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the business posted $3.00 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is presently 496.97%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.